The role of estrogen metabolism in aging

Journal of Musculoskeletal Neuronal Interactions

Volumn 3, Issue 4, 2003, Pages 370-373

  Westerlind, Kim C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

16 Hydroxyestrone; 2 Hydroxyestrone; Cancer; Osteoporosis

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRADIOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CATECHOL ESTROGEN; CYTOCHROME P450; ESTRADIOL; ESTROGEN; ESTRONE; ISOFLAVONOID; LIGNAN; TESTOSTERONE 17BETA DEHYDROGENASE; THYROID HORMONE;

AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BONE MASS; BONE STRENGTH; BREAST CANCER; CABBAGE; CANCER RISK; DRUG MECHANISM; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; FEMALE; HUMAN; HYDROXYLATION; LINSEED; MALE; MENOPAUSAL SYNDROME; METABOLITE; METHYLATION; MODULATION; NUTRITIONAL VALUE; OXIDATION; PHYSICAL ACTIVITY; PROSTATE HYPERTROPHY; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING; SULFONATION; TARGET CELL; TISSUE SPECIFICITY; UTERINE CERVIX CANCER;

EID: 1642431875     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19:1-27.
2. Liehr JG. Mechanism of metabolic activation and inactivation of catechol estrogens: a basis of genotoxicity. Polycyclic Aromatic Compounds 1994; 6:229-239.
3. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993; 57:237-257.
4. Schneider J, Hub MM, Bradlow HL, Fishman J. Anti-estrogen activation of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984; 259:4840-4845.
5. Martucci C, Fishman J. Direction of estrogen metabolism as a control of its hormonal action - uterotropic activity of estrogen metabolites. Endocrinology 1977; 101:1709-1715.
6. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schewlegerer L. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppressed tumor growth. Nature 1994; 368:237-239.
7. Bradlow HL, Telang NT, Spekovic DW, Osborne MP. 2-Hydroxyestrone: the "good" estrogen. J Endocrinol 1996; 150(Suppl.):S259-265.
8. Aldercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E. Estrogen metabolism and excretion in oriental and Caucasian women. J Natl Cancer Inst 1994; 86:1076-1082.
9. Fishman J, Martucci C. Biological properties of 16α-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocr Metab 1980; 51:611-615.
10. Swaneck GE, Fishman J. Covalent binding of endogenous estrogen 16α-OHE1 to estrogen receptors in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988; 85:7831-7835.
11. Westerlind KC, Gibson KJ, Evans GL, Turner RT. The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 2000; 170:165-174.
12. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996; 93:3294-3296.
13. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2/16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11:635-640.
14. Meilahn EN, DeStavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78:1250-1255.
15. Fishman J, Schneider J, Herschopf RJ, Bradlow HL. Increased estrogen-16-alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984; 20:1077-1081.
16. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, Osborne MP, Fishman J. Estrogen metabolite ratios and risk assessment of hormone-related cancers: Assay validation and prediction of cervical cancer risk. Ann N Y Acad Sci 1995; 768:312-316.
17. Telang NT, Avelrod DM, Wong GY, Bradlow HL, Osborne MP. Biotransformation of estradiol by explant culture of human mammary tissue. Steroids 1991; 56:37-43.
18. Muti P, Westerlind K, Wu T, Grimaldi T, DeBerry J, Schunemann H, Freudenheim J, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control 2002; 13:947-955.
19. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP. Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg 2001; 124:241-247.
20. Bucala R, Lahita RG, Fishman J, Cerami A. Increased levels of 16α-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus. J Clin Endocr Metab 1985; 60:841-847.
21. McAlindon TE, Gulin J, Chen T, King, T, Lahita R, Nuite M. Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 2001; 10:779-783.
22. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL. Preliminary results of use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998; 118:810-815.
23. Lee SH, Kim KM, Jung BH, Chung WY, Park CS, Chung BC. Estrogens in female thyroid cancer: alteration of urinary profiles in pre-and post-operative cases. Cancer Lett 2003; 189:27-32.
24. Lotinun S, Westerlind KC, Turner RT. Tissue-selective effects of continuous release of 2-hydroxy and 16α-hydroxyestrone on bone, uterus, and mammary gland in ovariectomized rats. J Endocrinol 2001; 170:165-174.
25. Westerlind KC, Gibson K, Malone P, Evans GL, Turner RT. Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 1998; 13:1023-1031.
26. Lim SK, Won YJ, Lee TH, Kwon SH, Lee EJ, Kim KR, Lee HC, Hah KB, Chung BC. Altered hydroxylation of estrogen in patients with postmenopausal osteopenia. J Clin Endocr Metab 1997; 82:1001-1006.
27. Leelawattana R, Ziambaras K, Roodman-Weiss J, Lyss C, Wagner D, Klug T, Armamento-Villareal R, Civitelli R. The oxidative metabolism of estradiol conditions postmenopausal bone density and bone loss. J Bone Miner Res 2000; 15:2513-2520.
28. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996; 276:1404-1408.
29. Zhang Y, Kiel DP, Kreeger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336:611-617.
30. Fowke JH, Longcope C, Herbert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9:773-779.
31. Haggans CJ, Travelli EJ, Thomas W, Martinin MC, Slavin JL. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9:719-725.
32. Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000; 60:1299-1305.
33. Ward WE, Yuan YV, Cheung AM, Thompson LU. Exposure to flaxseed and its purified lignan reduces bone strength in young but not older male rats. J Toxicol Environ Health 2001; 63:53-65.
34. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Morrill M, Warren J. The effect of a low-fat diet on estrogen metabolism. J Clin Endocr Metab 1987; 64:1246-1250.
35. Schneider J, Bradlow HL, Strain G, Levin J, Anderson K, Fishman J. Effects of obesity on estradiol metabolism: decreased formation of non-uterotropic metabolites. J Clin Endocr Metab 1983; 56:973-978.
36. Fowke JH, Longcope C, Herbert JR. Macronutrient intake and estrogen metabolism in healthy postmenopausal women. Breast Cancer Res Treat 2001; 65:1-10.
37. Michnovicz JJ, Herschcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986; 315:1305-1309.
38. Thompson DS, Krishner MA, Klug TL, Kastango KB, Pollock BG. A preliminary study of the effect of fluoxetine treatment on the 2/16α-hydroxestrone ratio in young women. Ther Drug Monit 2003; 25:125-128.
39. Michnovicz JJ, Galbraith RA. Effect of exogenous thyroxine on C-2 and C-16α hydroxylations of estradiol in humans. Steroids 1990; 55:22-26.
40. Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 2001; 10:287-301.
41. Zhu BT, Liehr JG. Inhibition of catechol-O-methyltransferase-catalyzed-O-methylation of 2- and 4-hydroxyestradiol by catecholamines: implications for the mechanism of estrogen-induced carcinogenesis. Arch Biochem Biophys 1993; 304:248-256.
42. Ursin G, London S, Yang D, Tseng CC, Pike MC, Bernstein L, Stanczyk FZ, Gentzschein E. Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 2002; 72:139-143.
43. Westerlind KC, Gibson KJ, Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease risk assessment. Steroids 1999; 64:233-243.
44. Thibodeau PA, Kachadourian R, Lemay R, Bisson M, Day BJ, Paquette B. In vitro pro- and antioxidant properties of estrogens. J Steroid Biochem Mol Biol 2002; 81:227-236.
45. Seeger H, Mueck AO, Lippert TH. The effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sci 1997; 61:865-868.